FindTrial
Sign In

Dextroamphetamine as an Adjunct in Cocaine Treatment - 1

Dextroamphetamine as an Adjunct in Cocaine Treatment

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000304
Enrollment
120
Registered
1999-09-21
Start date
1997-08-31
Completion date
2001-08-31
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine-Related Disorders, Substance-Related Disorders

Keywords

cocaine dependence

Brief summary

The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the replacement strategy.

Interventions

DRUGDextroamphetamine

15 mg for first 8 weeks and 30 mg for 2nd 8 weeks

DRUGD-Amphetamine

30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)

DRUGPlacebo

Placebo

Sponsors

University of Texas
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
verifiable cocaine abstinence16 weeks of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026